Consistently, clinical data showed that tumor tissues with high DEGS2 levels had more advanced AJCC stage and higher serum CEA levels than those with low DEGS2 levels, which suggested a poor prognosis for CRC patients. This evidence concerns the gene DEGS2 and neoplasm.